Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.54 |
| ▸ | HTR1A | P08908 | 6/20 | 0.50 |
| ▸ | HTR3A | P46098 | 6/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336283 | 0.87 | ADRB1 (0.63) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| Hydrochloric Acid SCHEMBL6739727 | 0.85 | ADRB1 (0.61) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL10702371 | 0.81 | ALDH1A1 (0.56) | KDM4EALDH1A1 | |
| SCHEMBL8710559 | 0.80 | ALDH1A1 (0.46) | HTR3AKDM4EALDH1A1HTR3EHTR3B | |
| Acetamide SCHEMBL3242644 | 0.79 | ADRB1 (0.51) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL10836444 | 0.79 | ADRB1 (0.55) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL2218392 | 0.78 | SIGMAR1 (0.50) | ADRB1HTR3AKDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL3634792 | 0.78 | HTR2C (0.55) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL5745223 | 0.77 | ADRB1 (0.49) | ADRB1HTR1AHTR3AHTR7CYP1A2 | |
| SCHEMBL8700015 | 0.76 | HTR3A (0.58) | ADRB1HTR1AHTR3AHTR7HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| US-7615550-B2 | Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| US-5780472-A | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAZL CO., LTD. (KR) | 1998-07-14 | — | — | US | disclosed |
| EP-0749425-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARM. CO., LTD. (KR) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996021648-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | HRH3, HRH4, HRH2 | ADRB1 311/4885HTR1A 85/4885HTR3A 53/4885 |
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | ADRB1 239/4885HTR1A 39/4885HTR3A 30/4885 |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | ADRB1 4226/4885HTR1A 2476/4885HTR3A 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.